PFS and OS prediction in a prospective trial on resectable NSCLC: Dual time-point 18 FDG PET/CT before and after short term preoperative immune checkpoint inhibition outperforms pathological response assessment

relatlimab (BMS-986016) - BMS

Opdivo (nivolumab) - Ono Pharmaceutical, BMS

H. Hautzel 1; M. Wiesweg 2; T. Plönes 3, 4; D. Theegarten 5; D. M. Kersting 1; C. Aigner 3, 6; K. Herrmann 1; M. Schuler 2

Sep 29, 2026